FDA approves Lilly migraine new emgality for preventive treatment of adult migraines

recently, the U.SFood andDrug(
FDA(
FDA) has approved Lilly
's new drug(galcanezumab-gnlm) 120mg injection for the prevention of migraines in adultsEmgality will provide a monthly, self-injected subcutaneous injection drug for the adult migraine group, which is strictly prohibited for patients with severe allergies to galcanezumab-gnlm or any excipientabout EmgalityEmgality targets blocking the calcitonin gene-related peptide (CGRP) receptor, which plays a key role in the occurrence of migrainesCGRP is a neuropeptide that has been shown to be released during a migraine attack and is thought to be a trigger for a migraine attackAt present, CGRP receptors have become a hot target for the development of migraine drugsEmgality's approval is based on positive data from two Phase III clinical studies (EVOLVE-1, EVOLVE-2) conducted in patients with onset migraine (EM) and a Phase III clinical study (REGAIN) conducted in patients with chronic migraine (CM)The data showed that Emgality showed significant clinical and statistically significant results in reducing the number of migraine days per month compared to placeboIn addition to the three approved antibody drugs mentioned above, the of the Company (single anti-drug eptinezumab (1 in March) is also in phase III clinical development, and the drug has a response rate of up to 100% in some patients and is expected to be submitted for listing in 2018 in addition, a number of companies are developing oral CGRP inhibitors, including Aer jian's atogepant and Biohaven's rimegepant